Your energy drops by half between 25 and 60 - and there's more you can do about it than you think.
At 25, your cells are flush with a molecule that powers almost everything - from how fast you recover after a hard workout to how clearly you think at 4pm. By 60, you'll have half as much of it. The question isn't whether that decline matters. The question is what, if anything, you can do about it.
Nicotinamide adenine dinucleotide is not a wellness trend. It is a coenzyme present in every living cell, essential to over 500 enzymatic reactions - including the ones that govern DNA repair, mitochondrial electron transport, and the activation of sirtuins, the longevity-associated proteins first identified in Guarente's lab at MIT in the 1990s.
The decline is not disputed. Massudi et al. (2012) established a roughly linear fall in whole-blood NAD+ levels with age, with a 50% reduction measurable between the third and seventh decade of life. The mechanism is well-understood: as we age, the enzyme CD38 - a glycohydrolase involved in immune signalling - becomes progressively more active and consumes NAD+ faster than the salvage pathway can replenish it. Simultaneously, NAMPT activity, the rate-limiting enzyme in NAD+ biosynthesis, declines.
The precursor question
NAD+ cannot be supplemented directly - it does not survive oral delivery intact. The question has therefore always been which precursor provides the most efficient and bioavailable route to intracellular NAD+ repletion.
Three candidates dominate the literature: nicotinic acid (NA), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN). Nicotinic acid, the oldest, causes flushing at therapeutic doses via prostaglandin D2 release and is poorly tolerated. NR and NMN have become the focus of modern research precisely because they lack this side effect profile.
NMN sits one enzymatic step closer to NAD+ than NR in the salvage pathway. It is converted directly to NAD+ via NMNAT enzymes without the intermediate NR step. This theoretical advantage in conversion efficiency has been supported by the kinetic data: Mills et al. (2016) showed that oral NMN in mice was detectable in blood within 2.5 minutes and elevated hepatic NAD+ levels within 15 minutes - faster than equivalent NR supplementation in the same model.
What the human trials actually show
The first rigorous human pharmacokinetic study of NMN was published by Irie et al. (2020) in npj Aging and Mechanisms of Disease. Ten healthy men received a single oral dose of 100, 250, or 500 mg NMN. All doses elevated blood NMN levels significantly. At 500 mg, plasma NAD+ metabolites increased measurably within two hours. No adverse effects were reported at any dose.
Yoshino et al. (2021) in Science provided the first placebo-controlled RCT examining metabolic effects. Postmenopausal women with prediabetes received 250 mg/day NMN or placebo for 10 weeks. NMN significantly increased skeletal muscle NAD+ levels and improved insulin signalling - specifically, it enhanced muscle's ability to respond to insulin and upregulated the expression of genes involved in muscle remodelling. Fasting glucose and body composition did not change significantly, but the insulin sensitivity data was robust.
Liao et al. (2021) examined NMN in healthy middle-aged and older adults over 60 days. The 300 mg/day group showed significant improvements in telomere length - a proxy for biological age - compared to placebo. This was a secondary endpoint and requires replication, but the direction is consistent with the mechanistic hypothesis.
Huang et al. (2022) conducted a 12-week RCT in recreational runners aged 40–65. The 600 mg/day group showed significantly improved aerobic capacity (VO2 max) and muscle endurance compared to placebo. This is, to date, the best performance-relevant human data on NMN.
The dose-response evidence
Across the human trial literature, doses below 250 mg/day consistently show attenuated or negligible effects on NAD+ metabolites in blood. Doses of 500–600 mg/day appear to maximise intracellular repletion based on the current data. The effective window appears to be 300–600 mg/day, with diminishing returns above that threshold suggested by the pharmacokinetic curves in Irie et al.
Our Performance formula contains 500 mg NMN - at the upper end of the range supported by human trial data.
Bioavailability: the sublingual question
Sublingual NMN delivery has been proposed on the basis that it bypasses first-pass hepatic metabolism. Bhatt et al. (2023) found that sublingual administration in healthy adults produced higher peak plasma NMN concentrations than oral capsules at the same dose. However, the clinical significance of this difference on tissue-level NAD+ repletion remains to be established in longer-term trials. Oral delivery at sufficient dose remains the most-studied and validated approach.
What the evidence does not support
NMN is not a longevity guarantee. The human data on ageing endpoints - telomere length, epigenetic clocks, all-cause mortality - is preliminary. What the evidence supports is: NAD+ precursor supplementation at clinically-dosed levels reliably elevates intracellular NAD+ in humans, improves insulin sensitivity in at-risk populations, and shows promising signals in aerobic capacity. The mechanistic case for why this matters for long-term healthspan is strong. The direct human evidence that it extends lifespan is not yet available - and any brand claiming otherwise is not being honest with you.
